Rebiotix, a Ferring company, completes enrollment for phase 3 clinical trial of microbiota-based RBX2660

This article was originally published here

The Centers for Disease Control and Prevention (CDC) has classified C. diff as an urgent public health threat, with limited options for treatment. RBX2660 was developed under Rebiotix’s

The post Rebiotix, a Ferring company, completes enrollment for phase 3 clinical trial of microbiota-based RBX2660 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply